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Abstract
Background:  Breast  cancer  is  one  of  the  most  common  malignancies  affecting  women.  Recent
investigations  have  revealed  a  major  role  of  ion  channels  in  cancer.  The  transient  receptor
potential melastatin-2  (TRPM2)  is  a  plasma  membrane  and  lysosomal  channel  with  important
roles in  cell  migration  and  cell  death  in  immune  cells  and  tumor  cells.
Methods:  In  this  study,  we  investigated  the  prognostic  value  of  TRPM2  channel  in  breast  cancer,
analyzing public  databases  compiled  in  OncomineTM (Thermo  Fisher,  Ann  Arbor,  MI)  and  online
Kaplan-Meier  Plotter  platforms.
Results:  The  results  revealed  that  TRPM2  mRNA  overexpression  is  significant  in  situ  and  invasive
breast carcinoma  compared  to  normal  breast  tissue.  Furthermore,  multi-gene  validation  using
OncomineTM showed  that  this  channel  is  coexpressed  with  proteins  related  to  cellular  migration,
transformation,  and  apoptosis.  On  the  other  hand,  Kaplan-Meier  analysis  exhibited  that  low
expression  of  TRPM2  could  be  used  to  predict  poor  outcome  in  ER-  and  HER2+  breast  carcinoma
patients.
Conclusions:  TRPM2  is  a  promising  biomarker  for  aggressiveness  of  breast  cancer,  and  a  potential
target for  the  development  of  new  therapies.
© 2016  Hospital  Infantil  de  Me´xico  Federico  Go´mez.  Published  by  Masson  Doyma  Me´xico  S.A.
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Evaluación  del  canal  TRPM2  como  biomarcador  en  cáncer  de  mama  mediante  el
análisis  de  bases  de  datos  públicos
Resumen
Introducción:  El  cáncer  de  mama  es  la  neoplasia  maligna  más  común  que  afecta  a  mujeres.
Estudios recientes  han  revelado  un  papel  importante  de  los  canales  iónicos  en  el  cáncer.  El
receptor de  potencial  transitorio  melastatin-2  (TRPM2)  es  un  canal  que  se  expresa  en  la  mem-
brana plasmática  y  en  los  lisosomas;  posee  funciones  importantes  en  la  migración  y  muerte
celular de  células  inmunes  y  tumorales.
Métodos:  En  este  estudio  se  investigó  el  valor  pronóstico  del  canal  TRPM2  en  cáncer  mama.  Se
realizó el  análisis  de  bases  de  datos  públicos  empleando  las  plataformas  OncomineTM  (Thermo
Fisher, Ann  Arbor,  MI)  y  Kaplan-Meier  Plotter.
Resultados:  Los  resultados  mostraron  que  el  mRNA  de  TRPM2  se  sobreexpresa  significativa-
mente en  los  carcinomas  de  mama  in  situ  e  invasivo  en  comparación  con  el  tejido  mamario
normal. Además,  la  validación  de  múltiples  genes  empleando  OncomineTM  reveló  que  este  canal
se coexpresa  con  proteínas  relacionadas  con  la  migración  celular,  la  transformación  celular  y
apoptosis. Por  otra  lado,  el  análisis  de  la  sobrevivencia  promedio  usando  curvas  Kaplan-Meier
mostró que  la  baja  expresión  de  TRPM2  podría  utilizarse  como  un  marcador  de  pronóstico  pobre
en pacientes  con  carcinoma  de  mama  receptor  de  estrógeno  negativo  (ER-)  y  receptor  2  del
factor de  crecimiento  epidermal  positivo  (HER2+).
Conclusiones:  El  TRPM2  podría  emplearse  como  biomarcador  de  agresividad  en  cáncer  de
mama, y  como  blanco  para  el  desarrollo  de  nuevas  terapias.
© 2016  Hospital  Infantil  de  Me´xico  Federico  Go´mez.  Publicado  por  Masson  Doyma  Me´xico  S.A.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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b. Introduction
reast  cancer  is  the  most  common  malignancy  among
omen,  and  the  first  cause  of  death  in  this  population
orldwide  (Cancer  Today:  http://gco.iarc.fr/today/home).
hese  tumors  are  highly  heterogeneous,  and  although
remendous  advances  have  been  made  in  their  preven-
ion,  diagnosis,  and  treatment,  there  is  a  continuous  search
or  new  biomarkers  to  identify  new  subtypes  and  to  pre-
ict  their  clinical  behaviors  and  response  to  treatment.1--3
reast  cancer  is  subtyped  into  four  groups  according  to  the
xpression  of  estrogen  receptor  (ER),  progesterone  recep-
or  (PR)  and  human  epidermal  growth  factor  2  (HER2).
hese  groups  are  ER-positive  or  PR-positive/HER2-negative
ER+  or  PR+/HER2-);  ER+  or  PR+/HER2+;  ER-/PR-/HER2+
known  as  HER2+);  and  ER-/PR-/HER2-  (triple  negative).1--3
ost  breast  cancers  are  ER+,  which  are  well  differentiated
nd  less  aggressive  tumors,  and  have  a  better  prognosis
han  tumors  with  few  or  no  estrogen  receptors  (ER-/PR-
umors).1--3 Besides,  ER  expression  has  been  used  as  an
ndicator  of  endocrine  responsiveness  although  only  50%  of
R+  breast  tumors  respond  to  anti-estrogen  or  aromatase
nhibitors.  In  addition,  a  small  number  of  ER-  tumors  can
espond  to  hormonal  therapy.1--3 Moreover,  PR+  tumors  (65-
5%  of  all  breast  cancers)  are  hardly  ER-.  Consequently,  PR
as  been  used  to  discard  false  ER  negativity  that  would
xclude  some  patients  from  receiving  endocrine  therapy.
R+PR-  tumors  show  lower  mortality  rate  and  are  less
esponsive  to  endocrine  treatment  than  ER+PR+.  In  contrast,
R-PR-  tumors  have  higher  recurrence  rate,  lower  survival
nd  do  not  respond  to  endocrine  treatment.1--3
t
i
i
tOn  the  other  hand,  13-20%  of  invasive  ductal  breast
ancers  are  HER2+,  which  spread  more  quickly  than  other
ubtypes.  Likewise,  tumor  suppressor  TP53,  which  plays  a
ole  in  cell  proliferation,  survival,  apoptosis  and  genomic
ntegrity,  has  been  used  as  prognostic  marker  indepen-
ent  of  tumor  size,  node  status,  and  hormone  receptor
xpression.  Approximately  25--30%  of  breast  tumors  have  a
utation  on  TP53.1,4 Furthermore,  TP53-PR-  tumors  have
he  worse  prognosis  among  all  breast  cancers.1,4 Breast  can-
er  can  also  be  classified  based  on  the  status  of  ER,  HER2,
nd  the  proliferation  marker  KI67  into  five  intrinsic  sub-
ypes:  basal  (ER-/HER2-),  luminal  A  (ER+/HER2-/KI67  low),
uminal  B  (ER+/HER2-/KI67  high  and  ER+/HER2+),  HER  2+
HER2+/ER1-)  and  normal-like  tumors.1--3 Microscopically,
hey  are  also  grouped  into  grades  (1-3;  less  to  more  aggres-
ive),  indicating  the  speed  by  which  the  tumor  will  grow  and
xtend.1--3
Recently,  many  studies  have  investigated  the  role  of
on  channels  in  several  types  of  cancer,  including  breast
ancer.5--7 For  instance,  members  of  the  Transient  Recep-
or  Potential  (TRP)  channel  family,  TRPC1,  TRPC6,  and
RPM7  have  been  associated  with  cell  proliferation  in  breast
ancer.7 However,  studies  on  the  utility  of  these  proteins  as
iomarkers  are  still  scarce.  In  the  present  study,  we  inves-
igated  the  prognostic  value  of  the  TRPM2  channel  ----a  TRP
amily  member  involved  in  cell  migration  and  cell  death8----in
reast  cancer,  analyzing  public  databases.  We  found  consis-
ently  higher  expression  of  TRPM2  in  invasive  breast  tumors
n  comparison  to  in  situ  tumors  and  normal  tissue,  making
t  a promising  biomarker  for  aggressiveness  and  a  potential
arget  for  the  development  of  new  therapies.
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cEvaluation  of  TRPM2  channel  as  a  biomarker  in  breast  cance
2. Methods
2.1.  OncomineTM Platform  analysis
The  expression  of  TRPM2  gene  in  breast  cancer  was  ana-
lyzed  and  visualized  using  the  OncomineTM Platform  (Thermo
Fisher,  Ann  Arbor,  MI;  http://www.oncomine.org).9 For  this,
we  compared  TRPM2  mRNA  from  clinical  specimens  of
cancer  versus  normal  patient  datasets  with  more  than
151  samples.  We  selected  p  <  0.01  as  a  threshold,  1.5-fold
change  and  gene  rank  in  top  10%  because  these  values
are  analytical  and  statistically  significant.  We  analyzed
the  results  for  their  p-values,  fold  changes,  and  cancer
subtypes.
2.2.  Kaplan-Meier  Plotter  analysis
The  prognostic  value  of  TRPM2  gene  in  breast
cancer  was  analyzed  using  Kaplan-Meier  Plotter
(http://kmplot.com/analysis),  a  database  that  com-
bines  gene  expression  and  clinical  data.10,11 To  date,
Kaplan-Meier  Plotter  contains  information  of  54,675  genes
and  their  effect  on  survival  in  4,142  breast  cancer  patients
with  a  mean  follow-up  of  69,  40,  49  and  33  months.  We
focused  our  analysis  on  overall  survival  and  relapse-free
survival  patient  information  with  a  10-year  follow-up.
The  samples  were  divided  into  two  groups  (high  and  low
TRPM2  expression  levels)  using  the  median  gene  expression
value  and  were  compared  using  a  Kaplan-Meier  survival
plot.  The  hazard  ratio  with  95%  confidence  intervals
and  log  Rank  p-value  were  calculated  and  displayed.
We  used  the  best  specific  probes  (JetSet  probes)  that
recognized  TRPM2.
3. Results
3.1.  Differential  expression  of  the  TRPM2
transcript  in normal  and  malignant  breast  tissue
To  our  knowledge,  no  data  have  been  published  previously
on  TRPM2  expression  level  or  its  possible  prognostic  value  in
breast  cancer.  Therefore,  we  decided  to  perform  data  min-
ing  on  mRNA  expression  profiles  on  normal  and  malignant
breast  cancer  sets  in  the  OncomineTM Platform,  as  previ-
ously  described.  Three  independent  datasets  deposited  in
OncomineTM were  selected  to  identify  the  differential  mRNA
expression  of  TRPM2  channel  associated  with  breast  cancer.
OncomineTM-The  Cancer  Genome  Atlas  (TCGA)  interactive
interface  showed  501  different  tissue  samples  of  breast  car-
cinoma  and  61  of  normal  material.  As  shown  in  Figure  1,
TRPM2  was  significantly  overexpressed  in  389  invasive  duc-
tal  breast  carcinomas  (IDC)  compared  to  61  normal  breast
material  (fold  change  =  2.158,  Figure  1A).  Afterward,  we
performed  the  same  analysis  on  the  invasive  lobular  car-
cinoma  (ILC)  samples  from  the  TCGA  dataset.  We  found
that  TRPM2  expression  was  higher  in  ILC  when  compared
to  normal  breast  tissue  (fold  change  =  2.014,  Figure  1B),  as
well  as  in  invasive  breast  carcinoma  (fold  change  =  2.083,
Figure  1 C),  which  comprises  a  mixture  of  cancerous
a
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uctal  and  lobular  cells.  The  second  dataset  in  OncomineTM,
luck  dataset,  also  reflected  the  same  transcriptional  fea-
ures  for  TRPM2  in  154  invasive  breast  carcinomas  (fold
hange  =  1.476,  p  =  0.006;  Figure  1D)  compared  to  normal,
ven  though  there  were  only  four  samples  for  normal  tis-
ue.  Moreover,  the  analysis  of  the  third  dataset  (MA  dataset)
howed  that  this  channel  was  highly  expressed  in  11  sam-
les  of  ductal  carcinoma  in  situ  as  well.  Although  the  sample
izes  for  normal  and  ductal  carcinoma  in  situ  were  small,  the
-value  was  significant  (p  =  9.41  ×  10−6).  Consequently,  we
ext  compared  the  performance  of  TRPM2  channel  in  inva-
ive  versus  in  situ  ductal  carcinoma  using  the  TCGA  dataset.
hereas  the  database  had  only  three  in  situ  samples,  we
bserved  almost  a  six-fold  overexpression  of  this  gene  in
nvasive  carcinoma  (fold  change  =  5.599,  Figure  1F).  A  box-
lot  of  all  this  data,  which  compared  medians,  also  showed
he  data  to  be  significant.  Altogether,  these  analyses  sug-
est  that  the  increase  in  TRPM2  expression  is  associated
ith  cell  transformation,  particularly  to  invasive  carcinoma.
herefore,  this  protein  is  a  significant  predictor  of  tumor
nvasion.
.2.  High  TRPM2  mRNA  expression  correlates
ith invasive  breast  carcinomas
iven  that  cell  migration  requires  more  than  one  element,
e  figured  out  that  TRPM2  channel  is  not  the  only  one  gene
hat  is  highly  expressed  in  invasive  breast  carcinoma.  We
erformed  a  multi-gene  validation  using  OncomineTM-Gluck
ataset  to  point  out  the  highest  correlation  value  ∼1,  to  spot
hose  genes  coordinately  expressed  with  TRPM2.  This  vali-
ation  used  154  invasive  breast  carcinoma  and  four  normal
amples.
The  matching  gene  expression  pattern  filtered  15
haracterized  genes  [C7,  complement  component  7;
MEM217,  transmembrane  protein  217;  LDHAL6B,  lac-
ate  dehydrogenase  A-like  6B;  GAST,  gastrin;  CCDC149,
oiled-coil  domain-containing  149;  LOC100288839,  hypo-
hetical  protein  LOC100288839;  GUSB,  glucuronidase  beta;
CR3,  C-C  motif  chemokine  receptor  3;  ALPI,  intestinal
lkaline  phosphatase;  CELA3A,  chymotrypsin-like  elastase
amily  member  3A;  ENPP7,  ectonucleotide  pyrophos-
hatase/phosphodiesterase  7;  OPCML,  opioid  binding
rotein/cell  adhesion  molecule-like;  COL4A3,  collagen  type
V  alpha  3  (Goodpasture  antigen);  FLJ45244,  hypothetical
ocus  FLJ45244;  TDGF1,  teratocarcinoma-derived  growth
actor  1].  There  were  also  five  uncharacterized  genes
anked  in  the  top  10%  of  the  dataset  (Figure  2).  Inter-
stingly,  since  CCR3  was  recently  associated  with  breast
ancer  subtype,12 this  data  raised  the  possibility  of  studying
he  combined  effect  of  TRPM2  and  CCR3  overexpression
n  the  same  sample.  The  remaining  genes  were  examined,
nd  the  result  did  not  show  any  biological  process  over-
epresented.  Intriguingly,  these  proteins  are  related  to
nnate  and  adaptive  immune  response  (C7,  ALPI,  OPCML),
onnected  to  cancer  processes  (LDHAL6B,  GAST,  TDGF1),
nd  some,  like  ENPP7,  prevent  tumorigenesis.  Moreover,
hese  genes  are  reviewed  in  the  literature  as  a  route
r  function-related  to  cellular  migration,  transformation
r  apoptosis.
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Figure  1  Boxplot  results  of  a  meta-analysis  of  TRPM2  expression  in  normal  breast  and  invasive  carcinoma.  The  OncomineTM
dataset  was  reviewed  according  to  the  differential  analysis  order  by  over-expression  in  distinct  microarrays.  (A)  In  TCGA  dataset,
TRPM2 was  overexpressed  in  a  subset  of  invasive  ductal  carcinoma  compared  with  normal  breast  tissue  (p  =  1.69e-28)  and  (B)  in
invasive lobular  carcinoma  (p  =  5.80e-7)  and  showed  significantly  higher  expression  in  (C)  invasive  breast  carcinoma  (p  =  3.63e-10).
(D) In  Gluck  database,  TRPM2  was  overexpressed  in  invasive  breast  carcinoma  (p  =  0.006).  (E)  TRPM2  was  highly  expressed  in  eleven
samples of  ductal  carcinoma  in  situ  from  MA  dataset  (p  =  9.41e-6).  (F)  TRPM2  expression  was  significantly  higher  in  invasive  ductal
carcinoma than  in  ductal  carcinoma  in  situ, suggesting  that  the  use  of  this  channel  as  a  biomarker  should  be  investigated.  The
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.3.  Low  expression  of  TRPM2  mRNA  correlates
ith poor  outcome  in  patients  with  ER-  and  HER2+
reast cancer
ubsequently,  to  establish  the  prognostic  value  of  a  TRPM2
xpression  in  breast  cancer  overall  survival  and  relapse-free
urvival,  we  created  Kaplan-Meier  plots  of  mRNA  using  data
rom  Gene  Expression  Omnibus  (GEO;  Affymetrix  microar-
ays  only),  European  Generic  Association  (EGA)  and  TCGA
ompiled  in  an  online  plotter.  Indeed,  the  Kaplan-Meier
(
n
e
purves  of  overall  survival  of  ER-  (Figure  3A)  and  HER2+
Figure  3B)  patients  with  a  10-year  follow-up,  showed  a
orrelation  between  low  expression  of  TRPM2  and  lower  sur-
ival  rates.  In  contrast,  poor  patient  outcome  was  associated
ith  high  expression  of  TRPM2  in  the  subtypes  Luminal  B
Figure  3C),  TP53  wild  type  (Figure  3D),  ER+  and  grade  2
Figure  3E)  tumors.  Nevertheless,  p  values  were  less  sig-
ificant  than  ER-  and  HER2+  subtypes  (Figure  3).  TRPM2
xpression  level  had  no  influence  on  overall  survival  of
atients  with  HER2-,  Luminal  A,  mutated  TP53,  and  tumors
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Figure  2  Biological  associations  of  TRPM2  by  meta-signature  of  invasive  breast  carcinoma.  We  employed  the  web-based
OncomineTM-Gluck  microarray  database  to  analyze  biological  associations  of  high  mRNA  expression  in  invasive  breast  cancer.  We
compared cancer  tissue  (154  samples)  to  normal  tissue  (4  samples)  and  set  a  correlation  for  this  screening.  Heat  map  of  gene  expres-
inal
natu
E
A
s
o
o
u
4
R
n
T
t
o
i
asion across  from  red  stands  for  most  expressed,  yellow  for  marg
in invasive  cancer  compared  with  normal  tissue  counterpart  sig
of  grade  1  and  3  (Figure  3E).  Together,  these  data  suggest
that  mRNA  expression  of  TRPM2  as  a  predictor  of  out-
come  may  be  valuable  in  ER-  and  HER2+  breast  carcinomas
(p  =  0.0037  and  p  =  0.0094,  respectively).
Afterward,  we  analyzed  the  impact  of  TRPM2  mRNA
level  in  relapse-free  survival.  Figure  4  provides  statistically
significant  evidence  that  the  group  of  patients  with  low
expression  of  TRPM2  in  ER-,  HER2+,  Basal  and  Luminal  B
breast  cancer  presented  a  shorter  relapse-free  survival  time
than  the  panel  of  patients  with  high  expression  of  TRPM2.
On  the  other  hand,  ER+  and  HER2-  patients  with  high  TRPM2
expression  also  presented  shorter  relapse-free  survival  time
than  the  group  with  a  low  expression  of  TRPM2,  although
there  was  a  lower  significant  difference.  In  addition,  no
significant  difference  was  observed  between  both  groups
in  TP53  wild-type,  TP53  mutated,  luminal  A  subtypes  and
grades  1-3  (data  not  shown).In  general,  these  results  suggest  that  the  high  expression
of  TRPM2  may  be  used  as  a  biomarker  for  invasive  breast
carcinoma.  Conversely,  the  low  expression  of  TRPM2  may
predict  poor  outcome  and  a  higher  probability  of  relapse  in
w
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e
c and  blue  for  least  expressed.  Twenty  genes  are  overexpressed
res.
R-  and  HER2+  breast  carcinoma  patients  during  treatment.
lthough  the  results  showed  significant  differences  in  overall
urvival  and  relapse-free  survival,  p-values  were  higher  in
ther  subtypes;  therefore,  preliminary  and  further  analysis
f  more  public  data  should  be  performed  to  establish  the
tility  of  TRPM2  expression  as  a  biomarker  in  those  cases.
.  Discussion
ecent  studies  have  investigated  the  role  of  TRP  chan-
els  in  breast  cancer.5--7 For  instance,  TRPC1,  TRPC6,  and
RPM7  have  been  associated  with  cell  proliferation  in  these
umors.7 However,  few  investigations  have  been  conducted
n  other  TRP  members,  such  as  TRPM2,6 which  are  involved
n  cell  migration  and  cell  death,  critical  cellular  processes
ffected  in  cancer  cells.8 In  our  analysis,  using  OncomineTM,
e  found  that  TRPM2  is  highly  expressed  in  breast  carci-
oma  in  situ  in  comparison  to  normal  breast  tissue,  and
ven  expresses  nearly  six  times  more  in  invasive  breast  car-
inoma  samples  compared  to  the  in  situ  carcinoma  material.
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Figure  3  Low  expression  of  TRPM2  mRNA  correlates  with  poor  outcome  in  patients  with  ER-  and  HER2+  breast  cancer.  Kaplan-Meier
graphs show  the  overall  survival  prognosis  of  breast  cancer  patients  censored  at  120  months,  based  on  high  or  low  TRPM2  tumor
mRNA expression.  Patients  with  expression  above  the  median  are  shown  in  red,  and  patients  with  expression  below  the  median
in black.  (A)  ER-  breast  cancer  patients.  Upon  dividing  the  patients  by  TRPM2  mRNA  level,  those  with  low  expression  (n  =  37)  had
lower overall  survival  probability  over  time  (logrank  P  =  0.0037)  than  those  with  high  expression  (n  =  105).  (B)  HER2+  breast  cancer
patients. Patients  with  low  expression  (n  =  6)  had  lower  overall  survival  probability  over  time  (logrank  P  =  0.0094)  than  those  with
high expression  (n  =  22).  Curves  were  statistically  significant.  (C)  Conversely,  Luminal  B  breast  cancer  patients  with  high  expression
(n =  233)  had  lower  overall  survival  probability  over  time  (logrank  P  =  0.014)  than  those  with  high  expression  (n  =  87),  as  well  as
(D) patients  with  TP53  wild-type  breast  cancer.  Low  expression  (n  =  133),  high  expression  (n  =  54),  logrank  P  =  0.012.  Curves  were
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(tatistically significant.  (E)  Summary  of  hazard  ratios  (HR)  and
ER2-, Basal,  Luminal  A,  and  TP53  mutated  breast  cancer  subt
hese  results  strongly  suggest  that  TRPM2  could  be  used  as
 molecular  biomarker  of  tumor  invasion  in  breast  cancer.
ccordingly,  multi-gene  validation  using  the  OncomineTM-
luck  dataset  revealed  that  TRPM2  co-expressed  with
roteins  involved  in  cell  migration  (CCR3),  cancer  processes
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srank  P  values  of  overall  survival  curves  of  patients  with  ER+,
 and  grade  1-3  tumors.
LDHAL6B,  GAST,  TDGF1),  and  in  preventing  tumorigenesis
n  the  intestinal  tract  (ENPP7).  The  biological  relevance  of
hese  findings  is  still  unknown.  However,  a  recent  study  by
ong  DH  et  al.  has  demonstrated  that  higher  mRNA  expres-
ion  of  CCR3  indicates  a  reduced  risk  of  cancer  relapse  in
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Figure  4  TRPM2  mRNA  expression  correlates  with  relapse-free  survival  in  patients  with  breast  cancer.  Kaplan-Meier  graphs  show
the relapse-free  survival  prognosis  of  breast  cancer  patients  censored  at  120  months,  based  on  high  or  low  TRPM2  tumor  mRNA
expression. Red,  patients  with  expression  above  the  median;  black,  patients  with  expression  below  the  median.  After  splitting  the
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rt  wipatients by  TRPM2  mRNA  level,  those  with  low  expression  had  a
ER-, HER2+,  Basal  or  Luminal  B  subtype.  In  contrast,  high  TRP
slightly less  relapse  over  time  in  comparison  to  their  counterpaluminal-like  disease  but  not  in  triple-negative  breast  can-
cer  (TNBC)  and  HER2-  enriched  cancers.12 Additionally,  in
human  prostate  cancer,  the  expression  of  the  CCR3  receptor
is  associated  with  the  occurrence  of  aggressive  disease  with
w
h
v
der  probability  of  being  relapse-free  over  time  when  presented
xpression  patients  of  ER+  and  HER2-  breast  cancer  presented
th  low  expression.idespread  local  dissemination.13 On  the  other  hand,  TRPM2
as  been  involved  in  chemokine-  and  bacterial  peptide-  acti-
ated  directional  migration  and  oxidative  stress-induced  cell
eath  in  several  immune  cells.8 Furthermore,  recent  data
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nalysis  of  TRP  channels  in  cancer  showed  that  TRPM2  is
verexpressed  in  the  bladder,  head  and  neck,  liver,  and  lung
ancer  (adenocarcinoma).5 TRPM2  was  also  found  to  play  a
ole  in  prostate  cancer  and  melanoma.14,15 Besides,  TRPM2
hannel  silencing  in  breast  carcinoma  cell  lines  decreased
roliferation.6
Our  Kaplan-Meier  analysis  showed  that  low  TRPM2  could
e  used  to  predict  poor  outcome  and  a  higher  probability  of
elapse  in  ER-  and  HER2+  breast  carcinoma  patients  during
reatment.  Findings  of  this  study  suggest  that  TRPM2  might
e  a  potential  biomarker  and  target  for  new  therapies  for
ancer.  Further  analysis  of  more  public  data  should  be  per-
ormed  to  establish  the  utility  of  TPRM2  as  a  biomarker  in
reast  cancer  subtypes.
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